What does the patient actually hear in that first phone call to a clinic? A Wednesday afternoon at the kitchen counter, a list of three clinics on a notepad, the second one on the line: “We use the patient’s own cells.” Then a brochure arrives a week later from a fourth clinic that uses what the brochure calls “potent young donor cells from umbilical cord tissue.” The two cells are not the same kind of product. The two are not regulated the same way. The two do not carry the same risks, the same costs, or the same legal claims.
The vocabulary the reader encounters first is autologous and allogeneic. Autologous means cells taken from the patient and returned to the same patient. Allogeneic means cells from a donor, sometimes a relative, more often a tissue bank product derived from umbilical cord, placental, or adult bone marrow sources. The clinical difference between the two runs through immune response, regulatory category, procedure logistics, and cost in ways that shape what each can legally and clinically be used for.
Where Each Cell-Source Category Begins
Autologous treatment begins with a harvest from the patient’s body. Most often this means bone marrow drawn from the iliac crest under local anesthesia, or adipose tissue collected through a small lipoaspiration at the abdomen or flank. The harvest takes twenty to forty minutes. The processing, depending on the clinic, runs another thirty to sixty. The reinjection into the target joint or tendon happens the same day in most autologous orthopedic settings. Whoever walked in walks out with a bandage at the harvest site and a different one at the injection site, and the cells in both bandages came from the same body.
Allogeneic treatment begins somewhere patients never see. A donor consents to provide tissue. A tissue bank or cell-processing facility prepares the product. A sealed vial arrives at the clinic by overnight courier. The procedure on the day is the injection alone, no harvest, no recovery from a harvest site. The clinic story sounds simpler. The regulatory story is anything but.
A short list of what shapes the source decision:
- The condition under treatment, since some applications work better with the patient’s own cells and others rely on donor properties
- The patient’s own tissue health, since older patients or patients with certain conditions may have lower autologous cell yield
- The clinic’s regulatory pathway, since allogeneic products in non-relative settings sit under stricter FDA rules
- The price tag, since allogeneic products carry processing, banking, and shipping costs not visible at the consultation
How Donor and Same-Patient Cells Differ in Immune Response
Same-body cells carry the patient’s own surface markers. The immune system recognizes them. There is no graft to reject, and there is no donor immune cell present in the product to attack the recipient. Autologous transplants do not produce graft-versus-host disease, and immune reconstitution after the procedure runs faster than after a donor-cell procedure. The NIH NCBI Bookshelf chapter on transplant selection lays out the immune profile of the two approaches in the context where the difference matters most, which is hematopoietic transplant for cancer rather than orthopedic injection for joint disease.
Donor cells carry someone else’s surface markers. In the joint or tendon setting where most consumer-facing stem cell therapy operates, the products marketed as allogeneic are often described as “immune privileged,” meaning the cell type is said to provoke less immune response than ordinary donor cells would. The claim is partially accurate for some mesenchymal cell types and overstated for others. The mechanism remains a research-active question. What the patient should know is short:
- A donor product is not the same as the patient’s own cells, regardless of how the marketing describes it.
- The risk of an immune reaction is generally low for properly prepared mesenchymal donor products in joint settings, but it is not zero.
- The claim that donor cells from young tissue are more potent than autologous cells is one the published research does not consistently demonstrate at the level clinic marketing implies.
Regulatory Status: How FDA Treats Each Category Differently
The FDA framework for cellular products turns on a small set of criteria. Whether a product is minimally manipulated. Whether it is used for a homologous purpose, meaning the same basic function in the recipient as in the donor. Whether it has a systemic effect or relies on the metabolism of living cells for its primary function. Whether it is autologous, allogeneic from a first or second-degree relative, or allogeneic from an unrelated donor.
Products that meet the minimally manipulated, homologous-use criteria fall under Section 361 of the Public Health Service Act. These products require basic FDA registration and adherence to current good tissue practice. They do not require premarket approval. Most autologous joint injections in clinical practice today operate under this pathway, assuming the cells are not expanded in culture and not used for a non-homologous purpose.
Products that do not meet the criteria fall under Section 351 and are regulated as biologics. These products require an investigational new drug application or a full biologics license application before they may be legally marketed. The FDA framework page lays out the distinction in the formal regulatory language. The practical translation is shorter: the clinic that culture-expands cells, that uses cells for a non-homologous purpose, or that uses unrelated donor cells in most settings is offering a product that should have FDA premarket approval. If the clinic does not present that approval, the patient should ask why.
A short reference:
| Pathway | Common patient-facing applications | What the clinic must show |
|---|---|---|
| Section 361 | Autologous bone marrow concentrate, adipose-derived cells used same-day, related-donor in narrow contexts | Tissue establishment registration, current good tissue practice |
| Section 351 | Culture-expanded cells, unrelated allogeneic products, products with systemic effect or non-homologous use | Investigational new drug approval or biologics license |
The December 2024 FDA approval of an allogeneic bone-marrow mesenchymal stromal cell therapy for pediatric steroid-refractory graft-versus-host disease, as the ISCT MSC committee has documented, is one of the few allogeneic products to clear the Section 351 pathway in this category. Most allogeneic products marketed to consumers in joint and orthopedic settings have not.
What the Patient Experiences Differently With Each Approach
Procedure day for an autologous bone marrow harvest involves a thirty to sixty minute window of local anesthesia and harvest, processing time at the clinic, and the injection. Soreness at the harvest site can last several days. Adipose harvest involves a small lipoaspiration that some patients find more uncomfortable than the bone marrow draw, and others find easier. Either way, those who arrive walk out with two procedure sites and one bandage at each.
Procedure day for an allogeneic injection is shorter and gentler. The vial arrives. The patient is positioned for injection. The injection happens. The patient walks out with one small bandage. There is no harvest, no harvest-site recovery, and no second site to manage. This is the part of the allogeneic experience that drives patient appeal in the consumer market. It is also the part that makes the regulatory question more important rather than less.
A short comparison to carry into a consultation:
| Dimension | Autologous | Allogeneic |
|---|---|---|
| Harvest required | Yes (bone marrow or adipose) | No |
| Procedure time | 60 to 90 minutes total | 15 to 30 minutes total |
| Same-day discharge | Yes | Yes |
| Cell yield variability | Patient-dependent | Standardized per lot |
| Immune profile | No GvHD risk, faster reconstitution | Variable, product-specific |
| FDA pathway most common | Section 361 | Section 351 (most settings) |
Cost and Availability Implications of the Two Approaches
Autologous procedures price the harvest, the processing, the injection, the imaging guidance, and the clinic overhead into a single fee. The fee varies regionally and across clinics. Insurance coverage is generally absent in elective regenerative settings. The patient pays out of pocket or through an HSA arrangement.
Allogeneic procedures price the donor product, the processing chain, the shipping and handling, and the injection. The product itself often comes from a tissue bank or biotech provider, and the markup along the supply chain can be considerable. Allogeneic products marketed in clinical settings outside the few FDA-approved indications carry an additional risk premium worth hearing about: when the FDA enforces against unapproved Section 351 products, clinics offering them have been required to stop, refund, or both. Those who paid the full price for an unapproved allogeneic injection do not always get a refund, and the regulatory exposure is the clinic’s, not the consumer’s, until the consumer is the one whose treatment ends mid-protocol.
Questions to Ask Any Clinic About Their Cell Source
Six questions cover most of the source-related ground a patient should know to ask:
- Is the cell source autologous, allogeneic from a relative, or allogeneic from an unrelated donor?
- Is the product minimally manipulated and used for a homologous purpose, or is it culture-expanded or used for a non-homologous purpose?
- Under which FDA section is the product offered, 361 or 351?
- If 351, what is the investigational new drug or biologics license number?
- For allogeneic products, what is the tissue bank or supplier, and what donor screening was performed?
- For autologous products, where in the body is the harvest taken, and how is it processed?
The answers will not always come in this clean form. When a clinic struggles to answer these questions clearly, the consultation is leaving outside research to fill the gap. When a clinic answers them by naming sections and supplier names without hesitation, the consultation is operating closer to the level of transparency that patient-side decision-making tends to require.
The Wednesday afternoon at the kitchen counter ends with three notes on the patient’s notepad. One: the clinic that said “patient’s own cells” is operating an autologous product, most likely under Section 361. Two: the brochure that said “potent young donor cells from umbilical cord” is selling something that, depending on the manipulation and use, may sit under Section 361 or may sit under Section 351 without the corresponding approval. Three: the question of which option to consider depends on the condition, the cell type, the clinic’s regulatory standing, and a clear-eyed conversation that the consultation itself is meant to deliver.
The vocabulary alone is not the full principle. The vocabulary is autologous and allogeneic. The principle is what the FDA framework, the cell type, and the clinical setting together permit. Patients who learn the vocabulary alone often tend to choose on the basis of the brochure. Patients who learn the principle tend to choose on the basis of the regulatory and clinical fit, and by the end of the Wednesday phone calls, the patient closing the third notepad page has usually moved from one to the other.
Important note on cell-source decisions: No cell-source or processing approach removes the regulatory framework risk, and FDA distinctions between 351 and 361 products affect what clinics may legally offer. The realistic question is what documentation the patient asks for and what specific practices verify a clinic operates within current FDA guidance.
Sources: